[go: up one dir, main page]

WO2000072799A3 - Methode et compositions permettant de traiter la reponse inflammatoire - Google Patents

Methode et compositions permettant de traiter la reponse inflammatoire Download PDF

Info

Publication number
WO2000072799A3
WO2000072799A3 PCT/US2000/014548 US0014548W WO0072799A3 WO 2000072799 A3 WO2000072799 A3 WO 2000072799A3 US 0014548 W US0014548 W US 0014548W WO 0072799 A3 WO0072799 A3 WO 0072799A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory response
compositions
treating
pde
phosphodiesterase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/014548
Other languages
English (en)
Other versions
WO2000072799A2 (fr
Inventor
Joel M Linden
Gail W Sullivan
Ian J Sarembock
W Michael Scheld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UVA Licensing and Ventures Group
University of Virginia UVA
Original Assignee
University of Virginia UVA
University of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Virginia UVA, University of Virginia Patent Foundation filed Critical University of Virginia UVA
Priority to AU52941/00A priority Critical patent/AU5294100A/en
Publication of WO2000072799A2 publication Critical patent/WO2000072799A2/fr
Publication of WO2000072799A3 publication Critical patent/WO2000072799A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Des agonistes de récepteurs d'adénosine A2A, éventuellement combinés à un inhibiteur de phosphodiestérase (PDE) de type IV, sont efficaces pour le traitement de la réponse inflammatoire de tissus de mammaliens.
PCT/US2000/014548 1999-05-27 2000-05-26 Methode et compositions permettant de traiter la reponse inflammatoire Ceased WO2000072799A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU52941/00A AU5294100A (en) 1999-05-27 2000-05-26 Method and compositions for treating the inflammatory response

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32076999A 1999-05-27 1999-05-27
US09/320,769 1999-05-27

Publications (2)

Publication Number Publication Date
WO2000072799A2 WO2000072799A2 (fr) 2000-12-07
WO2000072799A3 true WO2000072799A3 (fr) 2001-07-12

Family

ID=23247801

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/014548 Ceased WO2000072799A2 (fr) 1999-05-27 2000-05-26 Methode et compositions permettant de traiter la reponse inflammatoire

Country Status (2)

Country Link
AU (1) AU5294100A (fr)
WO (1) WO2000072799A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
GB2372741A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,8-Disubstituted adenosine derivatives and their different uses
GB2372742A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
US20030013675A1 (en) * 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
JP4514452B2 (ja) 2001-10-01 2010-07-28 ユニバーシティ オブ バージニア パテント ファウンデーション Ａ２ａアゴニスト活性を有する２−プロピルアデノシン・アナログおよびその組成物
US20090170803A1 (en) * 2002-04-10 2009-07-02 Linden Joel M Adjunctive treatment of biological diseases
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050277615A1 (en) * 2004-05-17 2005-12-15 Can-Fite Biopharma Ltd. Pharmaceutical compositions having anti-inflammatory activity
WO2006015357A2 (fr) 2004-08-02 2006-02-09 University Of Virginia Patent Foundation Analogues de 2-propynyle adenosine comprenant des groupes 5'-ribose modifies presentant une activite agoniste a2a
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
CA2586845A1 (fr) * 2004-11-08 2006-05-11 Can-Fite Biopharma Ltd. Traitement therapeutique de resorption osseuse acceleree
EP2021350B1 (fr) 2006-03-21 2016-12-21 Rheinische Friedrich-Wilhelms-Universität Bonn Agonistes du récepteur a2a phosphorylé
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
KR101541791B1 (ko) 2006-05-04 2015-08-04 베링거 인겔하임 인터내셔날 게엠베하 다형태
WO2009114533A2 (fr) * 2008-03-10 2009-09-17 Cornell University Modulation de la perméabilité d'une barrière hématoencéphalique
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
EP4151218A1 (fr) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptine, dérivé de xanthine en tant qu'inhibiteur de dpp-4, destinée à être utilisée dans le traitement de sirs et/ou de sepsis
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
EP3110449B1 (fr) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Utilisation médicale d'un inhibiteur de dpp-4
WO2017211979A1 (fr) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinaisons de linagliptine et de metformine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998057651A1 (fr) * 1997-06-18 1998-12-23 Discovery Therapeutics, Inc. Compositions et procedes prevenant les restenoses consecutives a des interventions de revascularisation
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
WO1999034804A1 (fr) * 1998-01-08 1999-07-15 The University Of Virginia Patent Foundation Agonistes de recepteur d'adenosine a¿2a?

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
WO1998057651A1 (fr) * 1997-06-18 1998-12-23 Discovery Therapeutics, Inc. Compositions et procedes prevenant les restenoses consecutives a des interventions de revascularisation
WO1999034804A1 (fr) * 1998-01-08 1999-07-15 The University Of Virginia Patent Foundation Agonistes de recepteur d'adenosine a¿2a?

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BUSTER B(A) ET AL: "The effect of adenosine receptor agonists on neutrophil pleocytosis and blood-brain barrier pathophysiology in experimental bacterial meningitis", ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,XX,XX, vol. 37, 1997, pages 39, XP002104913 *
SULLIVAN ET AL.: "Neutrophil A2a adenosine receptor inhibits inflammation in a rat model of meningitis: synergy with type IV phosphodiesterase inhibitor , Rolipram", JOURNAL OF INFECTIOUS DISEASES, vol. 180, no. 5, November 1999 (1999-11-01), pages 1550 - 1560, XP000978330 *
SULLIVAN ET AL.: "Role of A2a adenosine receptors in inflammation", DRUG DEVELOPMENT RESEARCH, vol. 45, no. 3-4, 1998, pages 103 - 112, XP000978332 *
SULLIVAN GW ET AL: "The specific type IV phosphodiesterase inhibitor rolipram combined with adenosine reduces tumor necrosis factor-alpha-primed neutrophil oxidative activity", INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY,US,ELMSFORD,NY, vol. 17, no. 10, 1995, pages 793 - 803, XP002104914, ISSN: 0192-0561 *

Also Published As

Publication number Publication date
WO2000072799A2 (fr) 2000-12-07
AU5294100A (en) 2000-12-18

Similar Documents

Publication Publication Date Title
WO2000072799A3 (fr) Methode et compositions permettant de traiter la reponse inflammatoire
AU6230098A (en) Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
WO2002102314A3 (fr) Inhibiteurs puriques de phosphodiesterase (pde) 7
CA2400554A1 (fr) Derives de pyrimidine-4-one utilises comme inhibiteurs de ldl-pla2
GB9823871D0 (en) 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
GB9823873D0 (en) 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
EE200200192A (et) 5-(2-asendatud-5-heterotsüklüülsulfonüülpürid-3-üül)dihüdropürasolo[4,3-d]pürimidii n-7-oonid kui fosfodiesteraasi inhibiitorid
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
AU2085201A (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
ZA9811178B (en) Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors.
EP1443925B8 (fr) Derives de naphthyridine, preparation et utilisation en tant qu'inhibiteurs de l'isoenzyme phosphodiesterase 4 (pde4)
BG102879A (en) Carbolin derivatives
ZA200605901B (en) Pyrazolo [3,4-B] pyridine compounds, and their use as phosphodiesterase inhibitors
MXPA03005713A (es) Derivados de tetrahidropiridina, su preparacion y su uso como inhibidores de proliferacion celular.
WO2001044247A3 (fr) Agents et methodes de traitement des maladies hyperplasiques
WO2003086408A8 (fr) Utilisation d'agonistes du recepteur d'adenosine a2a dans le traitement de maladies inflammatoires
AU1025899A (en) Carboline derivatives as cgmp phosphodiesterase inhibitors
MY129445A (en) Compositions for treating inflammatory response
AU2001238665A1 (en) Method of identifying partial agonists of the a2a receptor
ZA9711317B (en) Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them.
WO2002028861A8 (fr) Procedes et composes pour le traitement de maladies proliferantes
WO2001087288A8 (fr) Traitement de la secheresse vaginale au moyen d'agonistes du recepteur de l'acetylcholine nicotinique
NO20015062L (no) Substituerte 3-cyano-[1.7],[1.5]og[1.8]-naftyridin- inhibitorer for tyrosin-kinaser
WO2003012051A3 (fr) Inhibiteur de methylation d'adn
AU4138601A (en) Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP